As such, just recently, Theruvath et al. presented an approach utilizing B7-H3-targeted chimeric antigen receptor (CAR) T cells for the treatment of AT/RTs [44], highlighting recent efforts to generate targeted therapies for the treatment of rhabdoid tumors. Here, CD276 is linked to ataxia telangiectasia.